Camurus' Interim Report January-March 2022
"Camurus had a strong start of the year with results heading in the direction of long-term profitability." Summary first quarter 2022 · Total revenues amounted to SEK 220 (126) million, an increase of 75% (67% at CER[1]),whereof product sales were SEK 202 (124) million, an increase of 63% (56% at CER) · Operating result was SEK 5 (-26) million, an increase of SEK 31 million · Cash position at the end of the quarter was SEK 400 (428) million · Full year 2022 outlook maintained · Market authorization for Buvidal[®] for the treatment of opioid dependence in Lebanon ·